Two Phase III studies of Lucentis (ranibizumab injection) in macular oedema due to retinal vein occlusion (RVO), have shown, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections. Results from both trials were presented at the Retina Congress 2009 meeting.
Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).
Anti-VEGF monotherapy appears to be an effective treatment for retinal angiomatous proliferation, according to results of a small, retrospective chart review. Although the results indicate that in most cases repeated injections would be needed to achieve improvement of stable vision, treatment based on ocular coherence tomography-confirmed presence of fluid could achieve outcomes similar to monthly injections.
Dr Anand Vinekar descibes how tele-ophthalmology models for ROP can be used in developing countries, using a successful Indian programme as a case study.
A review of the role and efficacy of anti-VEGF therapy in macular disease
Cataract surgery in patients with pre-existing AMD: Risks and Benefits
Canon Europe, revealed its new CX-1, a world first in retinal imaging technology for the first time at this year's ESCRS Congress.
A new study conducted by researchers at the University of Aberdeen, Scotland, has found that the brain predicts the consequences of eye movement even before the eyes take in a new scene.
High levels of the enzyme arginase contributes to vascular eye damage, and therapies to lower its levels could halt progression of diabetic retinopathy (DR), according to researchers at the Medical College of Georgia (MCG) School of Medicine, USA.
In a head-to-head comparison of six OCT devices, the Spectralis spectral domain OCT (Heidelberg Engineering) showed the lowest co-efficient of variation in a test-retest study.
Evaluation of a new value-based treatment approach for wet AMD.
In the second of a two-part article Drs Lombardi and Belilli present the results of a patient suffering with a wet maculopathy affecting both eyes.
Partial sections of vision were recently restored to a blind woman's retina through the use of gene therapy.
This month's Ophthalmology, the journal of the American Academy of Ophthalmology, reports on use of bevacizumab (Avastin), to benefit diabetic patients with macular oedema as well as people who develop cystoid macular oedema after cataract surgery.
The results of a study published in the July issue of Ophthalmology has discovered that people in the early stages of age-related macular degeneration (AMD) are at a higher risk of developing coronary heart disease (CHD), offering further support to the theory that AMD is associated with underlying systemic vascular disease.
Spanish researchers have used the induction of neuronal degeneration of intense light exposure in mice retina in an experimental model of retinitis pigmentosa.
Prevalence and incidence of advanced AMD can be catergorized as 'nature' or 'nurture' using a prediction model, based on genetic, environmental and demographic variables.
Microplasmin, the drug aimed at patients with focal vitreomacular adhesion, is to be trialled at Southampton General Hospital. Injected directly into the eye earlier clinical studies have indicated that it has potential to be effective without the risks associated with surgery.
Stemedica Cell Technologies, Inc., (Stemedica),a manufacturer and developer of clinical grade allogeneic adult stem cell technology, has discovered a significant breakthrough in the use of human stem cells and stem cell factors for the potential treatment of degenerations of the retina and retinal pigmented epithelium.
Stem cell technology for AMD treatment
Ozurdex, the first drug therapy for the treatment of macular oedema, following branch retinal vein occlusion or central retinal vein occlusion, has been approved by the FDA.
A biological marker for neovascular age-related macular degeneration (AMD) has been discovered by a team of researchers from the University of Kentucky.
A new suite of optical coherence tomography (OCT) software applications for the Cirrus HD-OCT has been cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution.
Dr Jayakrishna Ambati, professor and vice chairman of Ophthalmology and Visual Sciences at the University of Kentucky, has been chosen to receive the 2010 Cogan Award from The Association for Research in Vision and Opthalmology (ARVO).
The twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study investigating the efficacy and safety of combining Visudyne (Novartis Pharma AG) and Lucentis (Novartis Pharma AG, Genentech Inc.) have been released and so far are showing no significant differences.
